Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based medical research and telemedicine company with a clinic that provide ketamine treatments for persons with depression and related disorders. Through its medical solutions, it intends to reduce the illness burden of brain-based disorders, such as major depressive disorder, among others. The Company is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. It seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. The Company has clinic operations in the Canadian cities of Mississauga, Kitchener-Waterloo, Ottawa and Montreal. Its subsidiary, Braxia Health, is engaged in offering rapid onset treatments to aid those suffering from several treatment-resistant conditions, such as depression and bipolar disorder.


CSE:BRAX - Post by User

Post by Adwarion Apr 19, 2021 11:58am
306 Views
Post# 33022085

A dark cloud hangs over SHRM

A dark cloud hangs over SHRM

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Champignon Brands Inc. (SHRMF) Investors

April 19, 2021, 11:00 AM EDT

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Champignon Brands Inc. (“Champignon” or the “Company”) (OTC: SHRMF) securities between March 27, 2020 and February 17, 2021, inclusive (the “Class Period”). Champignon investors have until June 9, 2021 to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here to participate.

On June 22, 2020, Champignon announced that the Company had “been selected for continuous disclosure review by the British Columbia Securities Commission (the “Commission”) and “in connection with the review, the Commission had issued a cease trade order suspending in the securities of the Company pending the filing of business acquisition reports.”

On this news, the Company’s stock price fell 24% to close at $0.500 per share on June 22, 2020, thereby damaging investors.

On September 15, 2020, the Company issued a press release stating, amongst other things, “the Commission issued a replacement cease trade order . . . , pending the filing of a revised material change report . . . in connection with the acquisition by the Company of AltMed.” Champignon further stated that “the acquisition of AltMed should be treated as a reverse-takeover.”

On this news, Champignon’s stock price fell 5% to close at $0.271 per share on September 16, 2020, thereby damaging investors.

On February 17, 2021, Champignon announced that it would restate its financial statements for the three and six month periods ended March 31, 2020. Specifically, “the Company previously recognized intangible assets in connection with” certain acquisitions, and “management determined that . . . the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as result will be recorded as transaction costs in the Company’s statement of loss and comprehensive loss.” Champignon also stated that “a shareholder and contracted consultant (the ‘Consultant’) of the Company was a related party with respect to” those acquisitions.

On this news, Champignon’s stock price fell 10% to close at $0.687 per share on February 17, 2021, thereby damaging investors further.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Champignon had undisclosed material weaknesses and insufficient financial controls; (2) Champignon's previously issued financial statements were false and unreliable; (3) Champignon's earlier reported financial statements would need to be restated; (4) Champignon's acquisitions involved an undisclosed related party; (5) as a result of the foregoing and subsequent reporting delays and issues, the British Columbia Securities Commission would suspend Champignon's stock from trading; (6) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Champignon securities during the Class Period, you may move the Court no later than June 9, 2021 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you purchased Champignon securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210419005030/en/

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com

<< Previous
Bullboard Posts
Next >>